ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Net margin 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) net profit margin by fiscal year — reported net income divided by reported revenue.
-39.8%FY2024 · since FY2016: -504.1% → -39.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -39.8% | +149.1 pp |
| FY2023 | -188.9% | +420.6 pp |
| FY2022 | -609.5% | +1961.5 pp |
| FY2021 | -2571.0% | +715.8 pp |
| FY2020 | -3286.8% | +8938.2 pp |
| FY2019 | -12225.0% | -12064.5 pp |
| FY2018 | -160.5% | +24.9 pp |
| FY2017 | -185.4% | +318.8 pp |
| FY2016 | -504.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Gross profitADAPY Gross marginADAPY Operating incomeADAPY Operating marginADAPY Operating cash flowADAPY Free cash flowADAPY Capital expendituresADAPY Return on equityADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Total liabilitiesADAPY Shareholders’ equityADAPY overview →